Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Halabi, Susan"'
Autor:
Ryan, Charles J, Dutta, Sandipan, Kelly, William K, Middleberg, Rob, Russell, Carly, Morris, Michael J., Taplin, Mary-Ellen, Halabi, Susan
Publikováno v:
Clin Genitourin Cancer
Pre-treatment androgen levels are associated with overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) treated with androgen synthesis inhibitors. The current study sought to determine whether pre-treatment se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cfb1b4a1c7dcd8140902f35b023b69ef
https://europepmc.org/articles/PMC7252587/
https://europepmc.org/articles/PMC7252587/
Autor:
Armstrong, Andrew J., Humeniuk, Michael S., Healy, Patrick, Szmulewitz, Russell, Winters, Carolyn, Kephart, Julie, Harrison, Michael R., Martinez, Elia, Mundy, Kelly, Halabi, Susan, George, Daniel
Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1dfc8e0092d64467c05cfe03996ec999
https://europepmc.org/articles/PMC6309626/
https://europepmc.org/articles/PMC6309626/
Publikováno v:
Cancer, vol 120, iss 1
BackgroundThe current study was conducted to investigate the dependence between progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::d68a7b652734ed6424acad6804ab10d8
https://escholarship.org/uc/item/7652n3vw
https://escholarship.org/uc/item/7652n3vw
Autor:
Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F, Millard, Frederick, Stadler, Walter M, Morris, Michael J, Kantoff, Philip, Monk, J Paul, Carducci, Michael, Small, Eric J, Alliance for Clinical Trials in Oncology
Publikováno v:
Cancer, vol 119, iss 20
BackgroundPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::af0fe86e457be39148c2f3d5cf9a6e82
https://escholarship.org/uc/item/28d6p66f
https://escholarship.org/uc/item/28d6p66f
Autor:
Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F., Millard, Frederick, Stadler, Walter M., Morris, Michael J., Kantoff, Philip, Monk, J. Paul, Carducci, Michael, Small, Eric J.
Preliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe2980224bd5b187489daf345a5f9883
https://europepmc.org/articles/PMC3795898/
https://europepmc.org/articles/PMC3795898/
Autor:
Apolo, Andrea B, Ostrovnaya, Irina, Halabi, Susan, Iasonos, Alexia, Philips, George K, Rosenberg, Jonathan E, Riches, Jamie, Small, Eric J, Milowsky, Matthew I, Bajorin, Dean F
Publikováno v:
Journal of the National Cancer Institute, vol 105, iss 7
A prognostic model that predicts overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin-based chemotherapy was developed, validated, and compared with a commonly used Memorial Sloan-Kettering Cancer Center (MSK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::e32f6fdfe44c1656c36432154db32070
https://escholarship.org/uc/item/2nz9d4z5
https://escholarship.org/uc/item/2nz9d4z5
Publikováno v:
Cancer. 120(1)
The current study was conducted to investigate the dependence between progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediate endpoint
Autor:
Picus, Joel, Halabi, Susan, Kelly, W. Kevin, Vogelzang, Nicholas J., Whang, Young E., Kaplan, Ellen B., Stadler, Walter M., Small, Eric J.
The use of docetaxel prolongs survival for patients with castrate-resistant prostate cancer (CRPC). Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd90c9d72ca473edf3187a849e48ba73
https://europepmc.org/articles/PMC3010428/
https://europepmc.org/articles/PMC3010428/